TrialClinical rheumatology2020

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.

Jeffrey Kaine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.